Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Desflurane-induced Myocardial Protection

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by Keio University.
Recruitment status was:  Not yet recruiting
Sponsor:
Collaborator:
Baxter Healthcare Corporation
Information provided by (Responsible Party):
Nobuyuki Katori, Keio University
ClinicalTrials.gov Identifier:
NCT02019797
First received: December 18, 2013
Last updated: NA
Last verified: December 2013
History: No changes posted

December 18, 2013
December 18, 2013
January 2014
December 2015   (final data collection date for primary outcome measure)
Troponin I [ Time Frame: up to 3 days ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Length of ICU stay, Length of hospital stay [ Time Frame: up to 2 months after the surgery ] [ Designated as safety issue: No ]
  • Acute myocardial infarction [ Time Frame: up to 7 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Desflurane-induced Myocardial Protection
Desflurane-induced Myocardial Protection in Aortic Valve Surgery: A Pilot Study
This study examines pharmacological preconditioning and post conditioning of desflurane by comparing cardiac troponin release in patients receiving either desflurane or propofol for the aortic valve surgery.
Patients scheduled for aortic valve replacement with use of cardiopulmonary bypass are included in the study. Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a TIVA during the surgery. All patients receive a continuous infusion of remifentanil. Biomarker of myocardial damage troponin I is examined at 4 points; T1: after the induction of anesthesia, T2: arrival at ICU, T3: 12 hours after the ICU arrival, T4: 24 hours after the ICU arrival, T5: third post operative day (3POD).
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Aortic Valve Stenosis
Drug: Desflurane
Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
Other Name: SUPRANE
  • Experimental: Desflurane
    Desflurane inhalation at 1-2 MAC during surgery.
    Intervention: Drug: Desflurane
  • Active Comparator: Propofol
    5-8 mg/kg/hr infusion during surgery.
    Intervention: Drug: Desflurane
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
50
December 2016
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients scheduled for aortic valve replacement with use of cardiopulmonary bypass.

Exclusion Criteria:

  • Patients younger than 20 years old.
  • Recent myocardial infarction (within 1 year).
  • Renal dysfunction (GFR less than 50ml/min).
  • Known allergy to study drugs including propofol.
Both
20 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT02019797
Desflurane
Yes
Not Provided
Not Provided
Nobuyuki Katori, Keio University
Nobuyuki Katori
Baxter Healthcare Corporation
Study Chair: Makoto Suematsu, M.D., Ph.D Keio University, School of Medicine
Keio University
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP